Back to search

Article

Elbasvir/Grazoprevir with or without Sofosbuvir for Patients with Chronic Hepatitis C Virus Infection Post Solid Organ Transplantation

2024-01-31

Abstract excerpt

<h4>Background: </h4> A critical challenge in HCV therapy is managing patients who undergo solid organ transplantation. Elbasvir/grazoprevir, a combination of NS5A inhibitor and NS3/4A protease inhibitor, is considered a first-line treatment for chronic HCV infection. Elbasvir/grazoprevir is a newly approved treatment administered as a fixed-dose combination of NS5A inhibitor and NS3/4A protease inhibitor. It has...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bfd33c09-c4d6-54b0-bb71-623669ecd417
DOI
10.22541/au.170668846.69731822/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Elbasvir/Grazoprevir with or without Sofosbuvir for Patients with Chronic Hepatitis C Virus Infection Post Solid Organ TransplantationDOI 10.22541/au.170668846.69731822/v1
Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.Semantic proximity
Management of hepatitis c genotype 4 in the liver transplant setting.Semantic proximity
Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Semantic proximity
Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.Semantic proximity
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.Semantic proximity
Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.Semantic proximity
KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.Semantic proximity
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.Semantic proximity
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Semantic proximity
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.Semantic proximity
Select a neighboring publication to make it the new centre.